Sanofi Settlement Agreement Doj
A limited liability company formed by a former employee of Sanofi`s predecessor Ingenzyme Corporation filed the allegations in a lawsuit against whistleblowers. Under the provisions of the False Claims Act, individuals known as Relators may, on behalf of the government, take legal action for false allegations and participate in any recovery. Under the agreement announced today, the partnership will receive approximately $2.7 million in recovery. Big Pharma Sanofi-Aventis received $38.7 million on Thursday as part of a $465 million transaction with the False Claims Act by Mylan for knowingly classifying EpiPen as generic to avoid paying Medicaid rebates…. Continuous reading “Sanofi tried to undermine the Medicare program by using bribes disguised as routine charitable donations to help patients who were battling multiple sclerosis and faced expensive supplements,” said Joseph R. Bonavolonta, special agent in the Boston division of the FBI. “They manipulated the system, so that those who took his drug Lemtrada got an unfair advantage over patients who were taking other drugs, and with today`s regulations, they end up being held accountable.” There was no admission of misconduct in the comparison, Reuters reports. Sanofi entered into an agreement on the integrity of the company as part of the agreement. Under the terms of the transaction, Sanofi accepted the payment of $25,206,145 and also agreed to a two-year self-report on the effectiveness of its enhanced internal controls and the corruption and corruption compliance program. In announcing the transaction, the SEC highlighted Sanofi`s full cooperation in the investigation and its enhanced compliance measures.
Companies that have accounted for their charitable contributions include Astellas, Amgen, Jazz, Lundbeck, Alexion, Pfizer, United Therapeutics, Actelion, Mallinckrodt and Almirall. The transaction involves an investigation by the SEC and the U.S. Department of Justice (DOJ) into some local activities outside the United States and France, namely Kazakhstan, Jordan, Lebanon, Lebanon, Bahrain, Kuwait, Qatar, Yemen, Oman, the United Arab Emirates and the Palestinian territory between 2006 and 2015. As part of the transaction, the company does not admit or deny any wrongdoing. “According to the allegations made in today`s transaction agreement, Sanofi used an alleged charity as a channel to give money to patients taking Sanofi`s expensive drug, all at the expense of the Medicare program,” said Andrew E. Lelling, the U.S. Attorney General. “This office will continue to sue drug companies for violations of anti-kickback laws.
We commend Sanofi for quickly resolving the government`s accusations. Sanofi did not admit any wrongdoing in connection with the transaction. In the company`s statement, it defended the practice of financially supporting these charities and said it “believes these programs help patients lead healthier lives.” Sanofi has also entered into a Business Integrity Agreement (CIA) with the Department of Health and Human Services Office of Inspector General (HHS-OIG).